ENTYCE Provides the First Therapeutic Based on the Natural Physiology of Appetite Commenting on the launch, Ernst Heinen, DVM, PhD, Chief Development Officer of Aratana Therapeutics, stated that ...
LEAWOOD, Kan., Oct. 13, 2017 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative pet ...
As any pet owner can attest, when a dog stops eating it can be a source of major concern. With its recently approved product for dogs, Entyce, Aratana Therapeutics ...
LEAWOOD, Kan., May 17, 2016 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative ...
The US Food and Drug Administration's Center for Veterinary Medicine (CVM) has approved Aratana Therapeutics' Entyce for appetite stimulation in dogs. Aratana intends to commercially launch Entyce in ...
* Aratana Therapeutics - co is making Entyce commercially available to veterinarians in United States for appetite stimulation in dogs Source text for Eikon: Further company coverage: ...
Aratana Therapeutics ($PETX) has been promising investors three regulatory approvals this year, and now it’s two-thirds of the way toward reaching that goal. On May ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results